US 12,323,492 B2
Management of multiple devices within an analyte monitoring environment
Mark Sloan, Redwood City, CA (US); Nathan C. Crouther, San Francisco, CA (US); Glenn Berman, Alameda, CA (US); Gil Porat, Mountain View, CA (US); and Michael R. Love, Pleasanton, CA (US)
Assigned to ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed by ABBOTT DIABETES CARE INC., Alameda, CA (US)
Filed on Feb. 14, 2023, as Appl. No. 18/109,460.
Application 18/109,460 is a continuation of application No. 18/085,244, filed on Dec. 20, 2022.
Application 18/085,244 is a continuation of application No. 17/737,607, filed on May 5, 2022, granted, now 11,563,812, issued on Jan. 24, 2023.
Application 17/737,607 is a continuation of application No. 17/482,955, filed on Sep. 23, 2021, abandoned.
Application 17/482,955 is a continuation of application No. 16/455,481, filed on Jun. 27, 2019, granted, now 11,159,621, issued on Oct. 26, 2021.
Application 16/455,481 is a continuation of application No. 15/640,076, filed on Jun. 30, 2017, abandoned.
Application 15/640,076 is a continuation of application No. 14/717,749, filed on May 20, 2015, granted, now 9,723,082.
Claims priority of provisional application 62/001,343, filed on May 21, 2014.
Prior Publication US 2023/0199069 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. H04L 67/12 (2022.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); G16H 10/40 (2018.01); G16H 40/40 (2018.01); G16H 40/63 (2018.01); H04L 9/40 (2022.01); H04W 4/38 (2018.01); H04W 4/80 (2018.01); H04W 12/06 (2021.01); H04W 12/08 (2021.01); H04W 12/50 (2021.01)
CPC H04L 67/12 (2013.01) [A61B 5/0004 (2013.01); A61B 5/14532 (2013.01); A61B 5/6833 (2013.01); G16H 10/40 (2018.01); G16H 40/40 (2018.01); G16H 40/63 (2018.01); H04L 63/0807 (2013.01); H04W 4/38 (2018.02); H04W 4/80 (2018.02); H04W 12/06 (2013.01); H04W 12/08 (2013.01); H04W 12/50 (2021.01); A61B 5/7495 (2013.01); A61B 2562/08 (2013.01)] 27 Claims
OG exemplary drawing
 
1. An in vivo glucose monitoring system, comprising:
a reader device;
a first sensor control device configured to be powered on and disposed on skin of a user, the first sensor control device comprising a first glucose sensor, a first processor, and a first wireless communication circuitry,
wherein a first portion of the first glucose sensor is configured to be positioned under the skin and in contact with interstitial fluid of the user, wherein the first portion of the first glucose sensor comprises a first glucose-responsive enzyme and a first working electrode, and
wherein a second portion of the first glucose sensor is electrically coupled with glucose monitoring circuitry of the first sensor control device; and
a second sensor control device configured to be powered on and disposed on the skin of the user while the first sensor control device is also disposed on the skin, the second sensor control device comprising a second glucose sensor, a second processor, and a second wireless communication circuitry,
wherein a first portion of the second glucose sensor is configured to be positioned under the skin and in contact with the interstitial fluid of the user, wherein the first portion of the second glucose sensor comprises a second glucose-responsive enzyme and a second working electrode, and
wherein a second portion of the second glucose sensor is electrically coupled with glucose monitoring circuitry of the second sensor control device,
wherein the first glucose-responsive enzyme and the second glucose-responsive enzyme are both glucose oxidase,
wherein the first sensor control device is further configured to enter a warm-up period of the first sensor control device, and wherein the reader device is configured to display a first data indicative of the user's glucose levels from the first sensor control device after exiting the warm-up period of the first sensor control device, wherein the first data indicative of the user's glucose levels includes a first current glucose level, and
wherein the second sensor control device is further configured to enter a warm-up period of the second sensor control device, and wherein the reader device is further configured to display a second data indicative of the user's glucose levels from the first sensor control device during the warm-up period of the second sensor control device, wherein the second data indicative of the user's glucose levels includes a second current glucose level.